A Phase I Study of AK159 in Healthy Postmenopausal Women

Exclusion Criteria

• •Clinical abnormality identified in the laboratory tests
• •Weight \< 40.0 kg
• •Body mass index \< 17.5 or \>=30.5
• •History of disease of the kidneys, liver, heart, brain, or other organ that makes them ineligible as subjects
• •Previously received radiation treatment potentially affecting bone
• •Clinical abnormality identified in the 12-lead ECGs performed at the study center during the screening period
• •Systolic blood pressure \< 90 mmHg
• •Serum calcium level exceeding 10.4 mg/dL
• •History of contact dermatitis or skin disease potentially compromising study evaluation
• •Used drugs which impact bone metabolism in the 8-week period preceding investigational product administration
• •Used a bisphosphonate
• •Used a teriparatide product